Improving epilepsy management by targeting P2 × 7 receptor with ROS/electric responsive nanomicelles
TFP@A loaded with the P2 × 7 receptor antagonist showcases potential therapeutic benefits in suppressing NLRP3 inflammasome activation, mitigating microglial-neuron crosstalk, and ameliorating epilepsy symptoms, positioning it as a promising avenue for targeted epilepsy treatment.
Authors
- Huisheng Wu (ORCID: https://orcid.org/0000-0002-3264-1107)
- Ming Deng
- Zhaohong Kong (ORCID: https://orcid.org/0000-0001-6020-7992)
- Min Deng (ORCID: https://orcid.org/0000-0002-1952-4184)
- Jian Jiang (ORCID: https://orcid.org/0000-0002-5994-292X)
Institutions
- Wuhan University (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1186/s12951-025-03386-y
- Citations
- 1
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.12